Vardan S, Smulyan H
Am J Med Sci. 1982 Mar-Apr;283(2):99-105. doi: 10.1097/00000441-198203000-00009.
The proper place of thrombolytic agents in the management of pulmonary embolism is not yet well defined. A number of survivors of acute massive pulmonary thromboembolism remain in a delicate balance of hemodynamic compensation and where recurrent emboli could frequently be fatal. Successful response to urokinase therapy in such a case is presented and the status of currently available thrombolytic drugs is discussed. We suggest that thrombolytic therapy in massive pulmonary embolism would provide greater hemodynamic reserve, alleviate shock, minimize the chances of recurrent emboli and prevent permanent impairment to the pulmonary vascular bed.
溶栓药物在肺栓塞治疗中的恰当地位尚未明确界定。许多急性大面积肺血栓栓塞症幸存者的血流动力学代偿处于微妙平衡状态，在此情况下复发性栓塞常常可能致命。本文介绍了此类病例中尿激酶治疗的成功反应，并讨论了当前可用溶栓药物的情况。我们认为，大面积肺栓塞的溶栓治疗可提供更大的血流动力学储备，缓解休克，减少复发性栓塞的几率，并防止肺血管床的永久性损害。
